🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — October 26, 2026

Both filings relate to AutoZone Inc., an S&P 500 Consumer Discretionary constituent in the automotive retail group, so the digest is a single-company view rather than a cross-company comparison. The fiscal 2026 10-K shows solid top-line momentum, with net sales up 7.4% to about $20.34B, net income up 3.0%, and diluted EPS up 5.3% to $152.55, supported by 3.3% domestic comparable store sales growth and 374 net new stores. However, the headline 13.5% international comparable sales growth is largely a currency effect, as constant-currency growth slowed to 2.2% from 9.3% in FY2025. Capital structure is more aggressive: total debt rose about $278M to $9.08B while $2.03B of buybacks exceeded free cash flow after capital needs, and adjusted after-tax ROIC fell for a second consecutive year to 35.8%. The 8-K announcing CFO Jamere Jackson's departure on November 25, 2026 for FedEx is a governance event that introduces transition risk, though management characterized the strategy as well established. Net, the filings point to a mature compounder whose returns and leverage profile are becoming the central debate.

2 high priority 2 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — October 26, 2026

This Healthcare stream digest covers five SEC filings dated October 26, 2026, dominated by insider-selling disclosures from Intuitive Surgical (four Form 4 filings: a director, an SVP-HR, a VP Corporate Controller, and a director) plus one Johnson & Johnson venture-arm 13F-HR. Insider activity is uniformly negative in direction but almost entirely executed under Rule 10b5-1 plans, which substantially dilutes its signal value; the aggregate of roughly $11.9M in disclosed sales across the Intuitive filings (Guthart ~$9.08M, Widman ~$1.83M, Barratt ~$510K, Wadors ~$478K) reflects routine diversification and option-exercise activity rather than an obvious change in management conviction. The filings provide no period-over-period financial metrics, guidance, capital allocation, or M&A data, so trend analysis is limited to insider transaction patterns. The JJDC 13F shows a concentrated early-stage biotech/medtech book, with Protagonist Therapeutics the dominant reported value (~$345.07M) and several tiny positions indicating portfolio-tail housekeeping. Taken together, the day's news is primarily about concentrated insider liquidity at a single large-cap medtech name and modest portfolio disclosures from a strategic investor, with no clear sector-wide directional catalyst. Materiality is moderate across the set, and most actionable follow-up lies in tracking Intuitive's next scheduled disclosures rather than acting on this day's filings alone.

4 high priority 1 medium 5 total filings
· daily

US Earnings Financial Results SEC Filings — October 26, 2026

Across the 37 filings, the dominant pattern is divergence between top-line strength and earnings or cash quality. Several names posted strong revenue and net income growth (Celestica +82.5% revenue, Vicor +78.5%, FirstCash +17.7%, Graybar +22.0%, Rambus +22.3%), yet many showed margin compression, rising working capital, or weaker operating cash flow (Celestica gross margin 13.0% to 11.0%, Vicor receivables up $61.8M, Greenbrier operating cash flow down roughly 85%). Acquisition and debt-funded growth is a second theme: Public Storage total assets rose 43.5% with $114.6M of transaction costs in Q3, Brown & Brown amortization rose 71.9% over nine months, and Clearwater Paper added $305M of borrowings. Rate and credit sensitivity shows up in financials and REITs, with Ladder's interest expense up 37.3% against 12.1% interest income growth, Cincinnati Financial's AOCI swinging to $(951)M, and Hartford's OCI loss of $1,472M from AFS fixed-maturity marks. Consumer and discretionary weakness is visible in Medifast (revenue down 27.7% nine-month, net loss $22.7M), JetBlue (fuel up 61%, net loss $257M in Q3), and Greenbrier (revenue down 24%). Shareholder returns remain active through buybacks (Rambus $135.9M, AutoZone $2.03B, Brixmor and Piedmont smaller programs), though several capital-return programs are being funded while cash balances shrink. Overall, the filings point to a selective earnings environment where quality of growth, funding structure, and cash conversion matter more than headline revenue.

37 high priority 37 total filings
· daily

US Executive Compensation Proxy SEC Filings — October 26, 2026

This Executive Compensation Insights digest covers 23 SEC DEF 14A proxy filings dated October 26, 2026, the large majority of which are procedural annual or special meeting notices rather than compensation disclosures. The most material developments cluster around Nasdaq and NYSE American listing-compliance pressure: XCF Global, Treasure Global, TScan Therapeutics, and AEON Biopharma are all seeking reverse stock split authority, and XCF faces a December 7, 2026 compliance deadline. A second theme is SPAC liquidity stress, with GP-Act III and Globa Terra both seeking deadline extensions that carry redemption and trust-dilution risk. Compensation-specific disclosures are limited to ScanSource (auditor change and pay-versus-performance tables), Espey Mfg. (CEO compensation actually paid rising from $651,079 in FY2024 to $934,073 in FY2026, roughly flat in FY2026 at +0.8%), and FactSet (multi-year NEO tables through fiscal 2026). Enriched period-over-period, insider, and capital-allocation fields are largely absent from the excerpts provided, so quantitative trend synthesis is constrained; the digest relies on the figures explicitly stated in each filing. Governance signals of note include concentrated dual-class control at Village Super Market and the reduced board size at Espey.

23 high priority 23 total filings
· daily

US IPO Pipeline SEC S-1 Filings — October 26, 2026

Six filings dated October 26, 2026 populate the US SEC IPO Pipeline stream, but the enriched period-over-period, insider, guidance and capital allocation fields are largely absent from the excerpts provided, so the synthesis is constrained to what the narrative text supports. The clearest IPO-pipeline activity is Anthropic's S-1 for a Nasdaq Global Select listing, which carries the highest materiality (8/10) because of a dual-class structure in which Class F stock gives the Founder LLC 50.1% of general voting power while economic interests are not proportionate, and a Long-Term Benefit Trust elects a board majority via Class T stock. LIS Technologies filed a firm-commitment IPO of 2,833,334 shares at an assumed $6.00 (range $5.00-$7.00) on Nasdaq Capital Market, led by Titan Partners, with no operating results in the excerpt to assess. Traws Pharma's S-1 is a resale registration tied to a $50M standby equity facility with Roth at a fixed 6.0% discount to VWAP, implying dilution risk for existing holders. First Tracks Biotherapeutics' S-1 covers a spin-off from AnaptysBio and shows a sharp decline in short-dated Treasury holdings from $249.0M (Dec 2024) to $63.3M (Dec 2025), a balance-sheet trend worth monitoring. Klotho/Greenland Mines and PUBLIC CO MANAGEMENT CORP are resale and business-combination registrations with limited narrative detail, so their investment read is largely procedural. Overall, the pipeline skews toward speculative small-cap listings and discounted equity lines rather than large, clearly priced offerings.

6 high priority 6 total filings
· daily

US SEC Trading Suspension Halt Orders — October 26, 2026

Three SEC 8-K filings dated around October 21-26, 2026 touch on US listing-status events: Elme Communities' NYSE delisting tied to a Plan of Sale and Liquidation, Zeo Energy's Nasdaq bid-price compliance extension, and Eve Holding's NYSE suspension and delisting of its public warrants for an abnormally low selling price. All three are within the stream's focus (trading suspensions, delistings, regulatory halts on US exchanges), so none are excluded. The filings supplied do not include period-over-period financial figures, insider transactions, capital allocation amounts, or forward-looking financial guidance, so the quantitative synthesis is limited and the analysis rests mainly on qualitative event data and dates. The dominant theme is that two of three events are exchange-driven listing-status changes rather than operating news, with Elme being a voluntary wind-down and Eve and Zeo being price-related listing deficiencies. Investors should treat the Elme event as the most material (8/10) because it removes the common shares from a major exchange and is contingent on a liquidating trust process, while Zeo and Eve carry lower near-term market impact but flag persistent share-price weakness.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — October 26, 2026

Across the 34 filings in this 2026-10-26 window, the dominant theme is executive and board turnover rather than financial performance: roughly two-thirds of the filings are board appointments, resignations, or officer transitions, and only a handful (Clearwater Paper, VerifyMe/OpenWorld, Xtend AI, Health In Tech) carry quantitative or enriched financial content. The most material developments are the LiveWire Group CEO resignation with a Chief Restructuring Officer appointment and a Special Restructuring Committee (signaling a possible financing, sale, or recapitalization), the Seres Therapeutics and Earth Science Tech CFO departures ahead of filing deadlines, and the OpenWorld/VerifyMe preliminary Q3 figures showing ~$10.0M GAAP loss against $6.9M-$7.2M revenue, driven by ~$11.9M non-recurring stock compensation. Clearwater Paper is the only filing with a true period-over-period comparison set: Q3 2026 net sales fell to $385M from $399M, the net loss narrowed to $2M from $53M (which included a $48M goodwill impairment), and nine-month Adjusted EBITDA fell to $18M from $87M. The CFO rotation chain (AutoZone to FedEx, with Jamere Jackson moving to FedEx on November 30 and AutoZone opening an external search) and the Mark Young interim CFO appointment at MasterBrand during its American Woodmark integration are the clearest sector-level finance-leadership churn signals. Insider and capital-allocation data are largely absent from these 8-Ks, so most conviction reads must be inferred from governance structure rather than disclosed trades.

34 high priority 34 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 26, 2026

This USA Bankruptcy & Insolvency stream contains a single in-scope filing: Getty Images Holdings, Inc.'s 8-K disclosing voluntary Chapter 11 petitions filed October 21, 2026 in the U.S. Bankruptcy Court for the District of Delaware, alongside a DIP credit agreement dated October 23, 2026 with Cantor Fitzgerald Securities as administrative and collateral agent providing up to $143 million in new financing. With only one filing, cross-company period-over-period comparisons and sector-level aggregation are not meaningful; the excerpt also discloses no positive operating metrics, guidance, or insider activity. The dominant market implication is a distressed capital structure in which prepetition secured lenders, including Koch Equity Development LLC and its related parties on the prepetition EUR Term Loan, are receiving adequate protection payments while DIP liens and carve-out provisions reorder recovery priority. Equity and junior creditor recoveries appear at high risk, and the filing's 9/10 materiality reflects the scale of the restructuring event rather than any verifiable improvement in operations.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — October 26, 2026

The stream covers 34 US SEC filings dated October 26, 2026, almost all of them 8-K Item 5.02 disclosures of officer, director, or board changes. Two dominant themes emerge: a cluster of CFO and senior-officer transitions (FedEx/AutoZone, MasterBrand, Seres, Clearwater-adjacent governance, NetScout COO, Earth Science Tech CFO, Xtend AI COO) and a steady flow of routine independent-director appointments that add board depth without changing financial trajectory. The most material developments are the LiveWire Group CEO exit with a Chief Restructuring Officer and special restructuring committee (signaling a possible financing, sale, or recapitalization), the Health In Tech founder-to-CEO handover tied to an existing Nasdaq compliance issue, and the VerifyMe/OpenWorld reverse-takeover preliminary Q3 results showing $6.9-7.2M revenue against a roughly $10.0M GAAP net loss. Several filings carry no period-over-period financial data, so trend analysis is limited to the Clearwater Paper Q3 results (net sales down to $385M from $399M, net loss narrowed to $2M from $53M, nine-month Adjusted EBITDA down to $18M from $87M) and the VerifyMe preliminary figures. Governance-quality concerns surfaced in Cycurion (director independence lapse tied to law-firm payments) and Gladstone's multi-entity Wilkinson resignation, while the FedEx CFO appointment and Nasdaq/Ekholm board addition read as positive credentialing. Sentiment is predominantly neutral, with negative and mixed tones concentrated in restructuring, abrupt executive exits, and preliminary loss disclosures.

34 high priority 34 total filings
· daily

USA Insider Trading Pulse — October 26, 2026

The USA Insider Trading Pulse for 2026-10-26 covers 50 SEC Form 4 filings, of which 49 fall within the insider-transaction scope and one (Gladstone-family entity beneficial-ownership reports are in scope; the excluded item is a Pine Tree SPAC disposition flagged below as marginal) was retained. Activity is dominated by routine equity compensation (director RSU and restricted stock awards at Vylor, Acuity, Andersons, MillerKnoll, Fiverr, New York Times) and tax-withholding dispositions (Applied Optoelectronics across five insiders at $77.32, MillerKnoll, Acuity), which carry low signal value. Discretionary open-market selling is concentrated in the largest-cap names: Intuitive Surgical director Gary Guthart sold ~$9.08M, MSCI's General Counsel sold ~$1.48M, and Dell's director Lynn Radakovich sold ~$930K, most under Rule 10b5-1 plans, which reduces their informational content. The only clear open-market accumulation is Bluerock Private Real Estate Fund director Ramin Kamfar, who bought roughly $2.1M across two tranches at $12.42-$12.52. Period-over-period comparisons are largely absent from these Form 4 filings, so trend analysis relies on transaction-level data rather than YoY or QoQ financials. Net, the day's pulse is predominantly sell-side discretionary activity in a few large caps against broad director compensation accrual, with limited aggregate directional conviction.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — October 26, 2026

Across the 17 filings, M&A and SPAC-related activity dominated, with a mix of completed deals, pending combinations, and SPAC deadline and governance events. The clearest completed transaction is Francisco Partners' ~$650M all-cash take-private of Weave Communications at $7.40/share (~34% premium to the unaffected August 17, 2026 close), which is the most valuation-relevant development in the set. SPAC activity is bifurcated: Amanat/Corxel (~$377M gross proceeds, first-half 2027 close) and Senti Biosciences' CVR-only divestiture show deal flow, while Bold Eagle, Oaktree III and K&F II face deadline extensions or structural changes, and YHN Acquisition I faces Nasdaq delisting. Period-over-period data is sparse for deal filings; the only quantified comparisons come from Ponce Financial (Q3 2026 net income of $18.0M vs $8.2M QoQ, but with declining capital ratios) and Senti's pro forma reduction in total assets from $33.1M to $3.2M. Several filings (Nathan's Famous, Boston Omaha, Unitil, Faraday/FFR) carry transaction disclosures but limited verifiable financials, so conclusions there are provisional. Overall, the theme is redemption and deadline pressure across the SPAC cohort alongside selective strategic exits and take-privates.

17 high priority 17 total filings
· monthly

US Pre-Market SEC Filings Roundup — October 26, 2026

The overnight US SEC filing set (Oct 25-26, 2026) is dominated by a handful of high-materiality corporate events rather than broad earnings flow: the EQT/Range all-stock merger (pro forma EV above $50B, 0.987 EQT shares per Range share, Q1 2027 close targeted), the Amanat/Corxel SPAC combination implying a $200M equity value, and Elme Communities' delisting and liquidation under a Plan of Sale. Several filings are 13F holdings snapshots (roughly 15 of 50) that carry no period-over-period data, so portfolio-level growth or margin trends can only be inferred from the few filings that report financials. Among those, Ladder Capital shows strong nine-month EPS growth ($0.66 vs $0.38) masking a 15.6% YoY decline in quarterly net interest income and a 37.3% jump in interest expense, a compression pattern that deserves attention. Capital allocation signals are concentrated in Korea: SK hynix is executing a roughly KRW 40 trillion treasury share program and has floated a special dividend of about KRW 16 trillion ahead of its October 28 Q3 release, while KB Financial completed a KRW 698 billion buyback. Clinical and regulatory news is mixed, with Eikon's TeLuRide-005 showing a 63.1% pooled ORR offset by 48.6% Grade 3+ TRAEs, and Phathom facing an FDA exclusivity challenge with a November 23 comment deadline. Small-cap financing stress is visible at Expion (Baby Shelf limit, float about $9M) and Cyber Enviro-Tech (VWAP-linked equity put facility), reinforcing dilution risk in the micro-cap segment.

13 high priority 37 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — October 24, 2026

This digest covers a single federal construction award totaling $96,728,838, made on 2026-09-01 by the Indian Health Service (HHS) to JAYNES CORPORATION of Albuquerque, NM, for the Alamo Navajo Health Center design-build project in Magdalena, NM. The stream is 0/1 defense-related, so the entire obligation is civilian (HHS/IHS), with no DOD exposure in this period. The dominant theme is a single civilian health-facility construction award rather than a multi-contract trend, which limits pattern analysis. The highest-conviction read is that the award was full and open competition, firm fixed price, and non-set-aside, which signals a competitive, contractor-risk-bearing project rather than a policy-driven or protest-protected one. The key watch item is that the data does not disclose whether JAYNES CORPORATION is publicly traded, so the award's materiality to any investable equity cannot be confirmed, and $0 outlays were reported as of the data date.

1 total filings
· daily

New Federal Contractors — October 24, 2026

Six new federal contract awards totaling $351,510,484 were recorded on October 24, 2026, with zero defense-related awards, so the entire digest is civilian-agency exposure across HHS/Indian Health Service, NASA, DOE, Labor, and GSA. The largest award is JAYNES CORPORATION's $96,728,838 firm-fixed-price design-build contract for the Alamo Navajo Health Center, a non-recurring construction job whose investment relevance depends on whether the company is publicly traded, which the data does not disclose. The most durable pattern is NASA's continued reliance on JPL-linked research via California Institute of Technology, which received two awards totaling $125,476,358, though both recipients are nonprofit and carry no equity exposure. Highest-conviction signal is the Accenture Federal Services $45,668,737 DOE BPA call, which sits inside a $289,323,851 base-plus-options vehicle running to 2032, though outlays remain $0 so revenue realization is unproven. The key watch item is outlay progression across the newly awarded contracts, since five of six show $0 or low outlays at award, and the largest bearish risk is that much of the aggregate value is contingent on option exercise rather than committed.

6 total filings
· daily

Significant Contract Modifications ($10M+) — October 24, 2026

Six significant contract modifications totaling $351,510,484 were recorded in this period, with zero defense-related awards; all six are civilian (HHS/Indian Health Service, NASA, Department of Energy, Department of Labor, GSA) and all are rated neutral on signal strength (average 3.0/10). The largest is JAYNES CORPORATION's $96,728,838 firm-fixed-price design-build award from the Indian Health Service, a single non-recurring construction job whose investment relevance depends on public/private status that the data does not disclose. Two California Institute of Technology awards from NASA (combined $125,476,358) reflect continued reliance on JPL-affiliated research, but Caltech is a nonprofit with no equity exposure. The highest-conviction signal is the Accenture Federal Services LLC Department of Energy BPA call ($45,668,737 obligated, $289,323,851 base-plus-options through 2032-07-27), which indicates durable multi-year civilian IT demand, though outlays are currently $0. The key watch item is whether outlays begin on the Accenture and JAYNES awards, since no revenue recognition is yet observable on either.

6 total filings
· daily

Contract Deobligations Alert — October 24, 2026

Six federal contract awards totaling $351,510,484 in obligations were reviewed, with zero defense-related awards; all six are civilian (HHS/Indian Health Service, NASA, DOE, DOL, and GSA), so no defense-sector signal is present in this stream. The dominant theme is civilian services and construction spending across diverse agencies rather than a single agency or sector trend. The highest-materiality award is JAYNES CORPORATION's $96,728,838 firm-fixed-price design-build contract for the Alamo Navajo Health Center from HHS/Indian Health Service, though the recipient's public/private status is undisclosed, limiting investment relevance. Accenture Federal Services LLC's $45,668,737 DOE BPA call, with a $289,323,851 base-plus-options value and $0 outlaid to date, is the most notable publicly traded exposure, but the realized revenue impact remains unobservable. The key watch item is the low outlay rate across the largest current awards: JAYNES and Accenture show $0 outlaid, and CLEAR LINCS LLC's $41,104,522 GSA order also shows $0 outlaid, so near-term revenue recognition is unproven.

6 total filings
· daily

Contract Option Exercises — October 24, 2026

Six federal contract option exercises totaling $351,510,484 were reviewed for the single-day period of October 24, 2026, with zero defense-related awards, so the entire digest is civilian in composition (HHS/Indian Health Service, NASA, DOE, DOL, GSA). The dominant theme is civilian agency spending spread across construction, space R&D, IT services and administrative support rather than any single agency trend. The highest-materiality award is JAYNES CORPORATION's $96,728,838 firm-fixed-price Indian Health Service design-build contract, though its investment relevance depends on public-company status the data does not disclose. Accenture Federal Services' $45,668,737 DOE BPA call, with $289,323,851 potentially available if all options are exercised, is the largest identifiable publicly traded exposure, but it has $0 outlayed so far. The key watch item is the $0 outlay status on the two largest awards (JAYNES and Accenture Federal), which leaves realized revenue impact unverified; all six signals are rated neutral given the lack of defense exposure, multi-year budget context, and public-market linkage in the underlying data.

6 total filings
· daily

Federal IT & Cybersecurity Contracts — October 24, 2026

This digest covers a single federal IT and cybersecurity award dated October 24, 2026, totaling $45,668,737 in obligations, with zero defense-related records and therefore a 0% defense / 100% civilian split. The sole award is Accenture Federal Services LLC's firm-fixed-price BPA call from the Department of Energy, with a base-plus-options value of $289,323,851 running through 2032-07-27. The dominant theme is civilian IT services modernization at DOE, and the highest-conviction read is that the award establishes a long-duration vehicle with meaningful option-driven upside for Accenture. The primary risk is that current outlays are $0, so realized revenue is not yet observable and the investment case depends on option exercise and actual order flow. Sample size is one record, so no cross-contract pattern or sector-wide budget trend can be drawn from this period.

1 total filings
· daily

NASA & Space Contracts Intelligence — October 24, 2026

This digest covers two NASA awards totaling $125,476,358 in obligations, both to the California Institute of Technology (Caltech) for work tied to the Jet Propulsion Laboratory (JPL), with zero defense-related records and a fully civilian split. The dominant theme is sustained NASA reliance on JPL-affiliated research: a $75,729,570 not-competed cost-plus-fixed-fee delivery order for JPL Lunar Drones (April 2026 to September 2028) and a $49,746,788 cost-plus-fixed-fee order for the AIRS/AMSU/HSB atmospheric sounding program (2018 to 2027). The highest-conviction observation is the concentration of both awards with a single nonprofit recipient, which provides no direct equity exposure but signals stable, sole-sourced civilian R&D funding flows. Both awards were rated neutral (signal strength 2/10), so no bullish or bearish equity signal is supported by this data. The key watch item is the outlay progression on the lunar drone award, which had only about 29% ($22.3M) spent against its $75.7M obligation, and any option exercises pushing toward its $76.7M ceiling.

2 total filings
· daily

All HHS Contracts — October 24, 2026

This digest covers a single HHS contract record totaling $96,728,838 in obligations, with zero defense-related awards, making the entire stream civilian. The dominant theme is Indian Health Service facilities construction, represented by one firm fixed price design-build award to JAYNES CORPORATION (Albuquerque, NM) for the Alamo Navajo Health Center in Magdalena, NM, running from 2026-09-01 through 2029-09-26. The highest-conviction read is limited: the award is material and was won under full and open competition, but it is a single non-recurring construction project with $0 outlayed as of the data provided, and the average signal strength across the stream is only 4.0/10. The key watch item is whether JAYNES CORPORATION is publicly traded, since the data does not disclose its ownership status, and the materiality of this award to any investor depends entirely on that answer.

1 total filings